Systematic Drug Repositioning for a Wide Range of Diseases with Integrative Analyses of Phenotypic and Molecular Data

被引:56
作者
Iwata, Hiroaki [1 ]
Sawada, Ryusuke [1 ]
Mizutani, Sayaka [2 ]
Yamanishi, Yoshihiro [1 ,3 ]
机构
[1] Kyushu Univ, Med Inst Bioregulat, Multiscale Res Ctr Med Sci, Div Syst Cohort,Higashi Ku, Fukuoka, Fukuoka 8128582, Japan
[2] Kyoto Univ, Inst Chem Res, Bioinformat Ctr, Kyoto 6110011, Japan
[3] Kyushu Univ, Inst Adv Study, Higashi Ku, Fukuoka, Fukuoka 8128582, Japan
关键词
INTERFERON-ALPHA; IN-VITRO; PREDNISONE; EXPRESSION; THERAPY; GEMCITABINE; DISCOVERY; ARTHRITIS; NETWORKS; PATIENT;
D O I
10.1021/ci500670q
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Drug repositioning, or the appslication of known drugs to new indications, is a challenging issue in pharmaceutical science. In this study, we developed a new computational method to predict unknown drug indications for systematic drug repositioning in a framework of supervised network inference. We defined a descriptor for each drug-disease pair based on the phenotypic features of drugs (e.g., medicinal effects and side effects) and various molecular features of diseases (e.g., disease-causing genes, diagnostic markers, disease-related pathways, and environmental factors) and constructed a statistical model to predict new drug-disease associations for a wide range of diseases in the International Classification of Diseases. Our results show that the proposed method outperforms previous methods in terms of accuracy and applicability, and its performance does not depend on drug chemical structure similarity. Finally, we performed a comprehensive prediction of a drug-disease association network consisting of 2349 drugs and 858 diseases and described biologically meaningful examples of newly predicted drug indications for several types of cancers and nonhereditary diseases.
引用
收藏
页码:446 / 459
页数:14
相关论文
共 74 条
  • [1] [Anonymous], 1992, The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines
  • [2] Drug repositioning: Identifying and developing new uses for existing drugs
    Ashburn, TT
    Thor, KB
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) : 673 - 683
  • [3] Acute viral myocarditis: role of immunosuppression: a prospective randomised study
    Aziz, Kalim U.
    Patel, Najma
    Sadullah, Tareen
    Tasneem, Habiba
    Thawerani, Hasina
    Talpur, Saeed
    [J]. CARDIOLOGY IN THE YOUNG, 2010, 20 (05) : 509 - 515
  • [4] Structure-activity relationships for In vitro and In vivo toxicity
    Blagg, Julian
    [J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 41, 2006, 41 : 353 - 368
  • [5] Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A
    Blake, Stephen J.
    Hughes, Timothy P.
    Lyons, A. Bruce
    [J]. EXPERIMENTAL HEMATOLOGY, 2012, 40 (08) : 612 - 621
  • [6] Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma
    Boell, Boris
    Bredenfeld, Henning
    Goergen, Helen
    Halbsguth, Teresa
    Eich, Hans T.
    Soekler, Martin
    Markova, Jana
    Keller, Ulrich
    Graeven, Ullrich
    Kremers, Stephan
    Geissler, Michael
    Trenn, Guido
    Fuchs, Michael
    von Tresckow, Bastian
    Eichenauer, Dennis A.
    Borchmann, Peter
    Engert, Andreas
    [J]. BLOOD, 2011, 118 (24) : 6292 - 6298
  • [7] Antibiotic susceptibility of Tropheryma whipplei in MRC5 cells
    Boulos, A
    Rolain, JM
    Raoult, D
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (03) : 747 - 752
  • [8] Burd J., 2013, GASTROENTEROL RES PR, V2013
  • [9] The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)
    Buske, C.
    Hoster, E.
    Dreyling, M.
    Eimermacher, H.
    Wandt, H.
    Metzner, B.
    Fuchs, R.
    Bittenbring, J.
    Woermann, B.
    Hohloch, K.
    Hess, G.
    Ludwig, W-D
    Schimke, J.
    Schmitz, S.
    Kneba, M.
    Reiser, M.
    Graeven, U.
    Klapper, W.
    Unterhalt, M.
    Hiddemann, W.
    [J]. LEUKEMIA, 2009, 23 (01) : 153 - 161
  • [10] Drug target identification using side-effect similarity
    Campillos, Monica
    Kuhn, Michael
    Gavin, Anne-Claude
    Jensen, Lars Juhl
    Bork, Peer
    [J]. SCIENCE, 2008, 321 (5886) : 263 - 266